Company Number: 13442273

Analysis Date: 2025-07-20 16:18 UTC

Financial Health Assessment for RAN PHARMACEUTICALS LTD (as of 30 June 2024)

---

1. Financial Health Score: B+

Explanation:
RAN PHARMACEUTICALS LTD shows a generally healthy financial position with solid net assets, positive working capital, and growing shareholder equity over the last three years. The company benefits from a healthy cash reserve and manageable current liabilities. Minor caution is warranted regarding the reliance on director loans which have increased substantially, indicating some external liquidity support.

---

2. Key Vital Signs

Metric	2024 Figure	Interpretation
Fixed Assets	£32,089	Stable investment in long-term assets, mostly in investments (£31,623) and some tangible assets.
Current Assets	£57,882	Healthy level of liquid and short-term assets, with cash and debtors increasing year-on-year.
Cash at Bank	£36,427	Strong cash position showing good liquidity and ability to meet short-term obligations.
Debtors	£21,455	Rise in amounts owed by customers; indicates growth but requires close monitoring for collection.
Current Liabilities	£31,796	Increased liabilities mainly due to loans from directors (£25,525), suggesting reliance on internal financing.
Net Current Assets	£26,086	Positive working capital, indicating the company can cover short-term debts comfortably.
Net Assets / Shareholders’ Funds	£58,175	Growing equity base reflects accumulated profits and retained earnings, a sign of business stability.
Director Loans	£25,525	Substantial increase in director loans; while providing liquidity, this may signal cash flow pressure.

---

3. Diagnosis: Financial Condition and Business Health

RAN PHARMACEUTICALS LTD exhibits signs of financial "vitality." The company maintains a healthy liquidity buffer with cash reserves and net current assets comfortably exceeding current liabilities, akin to a patient with a strong pulse and good hydration. The net asset growth over the last 3 years suggests the business is "gaining strength," accumulating retained profits steadily.

However, the sharp rise in director loans from £2,585 in 2023 to £25,525 in 2024 is a "symptom of distress" that warrants attention. This reliance on internal loans might indicate temporary cash flow constraints or strategic financing decisions. While director loans can be a flexible source of funds, excessive dependence could signal underlying issues, such as difficulties in obtaining external finance or uneven revenue inflows.

Debtor balances have increased significantly, reflecting either business growth or extended credit terms. This is generally positive but requires monitoring to avoid a buildup of "bad debts" which would reduce cash flow health.

The company has a single employee and operates in professional and management consultancy activities, suggesting a lean operational model with limited fixed cost burdens.

---

4. Recommendations to Improve Financial Wellness

• Strengthen Cash Flow Management:
  Monitor debtor collection closely to ensure timely payments. Consider incentivising early payments or tightening credit terms to avoid liquidity strain.

• Reduce Reliance on Director Loans:
  Explore alternative financing options like business loans, grants, or equity investment to diversify funding sources and reduce potential future risks related to director lending.

• Build Tangible Asset Base Prudently:
  While investments remain steady, consider if additional capital expenditure could support growth or efficiency improvements without overextending the balance sheet.

• Maintain Positive Working Capital:
  Continue to manage current assets and liabilities carefully to preserve the company's ability to meet short-term obligations comfortably.

• Regular Financial Review:
  Implement quarterly financial health checks to catch early signs of distress and adjust strategies proactively.

---